María Natalia Gandur Quiroga recently shared a post on LinkedIn:
“Study Uncovers Mutations and DNA Structures Driving Bladder Cancer.
- New mutations and DNA structures drive bladder cancer, according to a study from Weill Cornell Medicine and the New York Genome Center.
- APOBEC3 antiviral enzymes mutate DNA, triggering early-stage bladder cancer.
- Cisplatin chemotherapy causes bursts of mutations, helping cancer cells resist treatment.
- Extrachromosomal circular DNA (ecDNA) promotes therapy resistance in bladder cancer.
- This study highlights new therapeutic strategies for a hard-to-treat cancer.”